Stephen Hypes, DO
Retina Specialist · West Columbia, SCNPI 1184064669
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Genentech USA, Inc. at 57.2% of the total. Reporting peaked in 2024 at $2,787 and has fallen 68.5% since, to $879 in 2025.
Across 94 payments — averaging $53.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$641
- AbbVie$434
- Astellas Pharma US Inc$275
- Alcon$271
- Apellis Pharmaceuticals, Inc.$117
- plus $414 from 7 others
What the payments were for
- Consulting fees$2,29046%
- Food & beverage$2,73954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 30 | $2,877 |
| Regeneron Healthcare Solutions, Inc. | 14 | $641 |
| AbbVie(2 entities) | 17 | $434 |
| Astellas Pharma US Inc | 6 | $275 |
| Alcon | 2 | $271 |
| Apellis Pharmaceuticals, Inc. | 6 | $117 |
| Alimera Sciences, Inc. | 6 | $113 |
| Ocular Therapeutix, Inc. | 1 | $97 |
| Novartis | 4 | $62 |
| Coherus Oncology, Inc. | 3 | $58 |
| Eyepoint US, Inc. | 3 | $40 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$2,436
- Constellation$271
- Izervay$143
- EYLEA$127
- EYLEA HD$105
How this compares
$5,029 in reported general payments places this provider in the 70th percentile of 20 retina specialist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 187 | $9,730 |
| Brimonidine Tartrate | 56 | $3,565 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 86 | $1,342 |
| Dorzolamide Hcl | 65 | $1,245 |
| Ofloxacin | 93 | $1,067 |
| Ketorolac Tromethamine | 48 | $1,013 |
| Atropine Sulfate | 16 | $644 |
| Acetazolamide | 11 | $522 |
| Latanoprost | 47 | $392 |
| Timolol Maleate | 12 | $101 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in West Columbia
- Nitin NigamWest Columbia$2K
- Daniel WillWest Columbia$1K
- David JohnsonWest Columbia$851
- Hao TangCharleston$66K
- Carl BakerHilton Head Island$37K
- Adam PflugrathGreenville$13K
- Jeffrey GrossColumbia$7K
- Arman FarrRock Hill$5K
- James HallGreenville$4K
- Robert PrinziLittle River$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.